- Home
- IOVA vs BKU Comparison
IOVA vs BKU Comparison
Compare IOVA & BKU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- BKU
- Stock Information
- Founded
- IOVA 2007
- BKU 2009
- Country
- IOVA United States
- BKU United States
- Employees
- IOVA N/A
- BKU N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- BKU Savings Institutions
- Sector
- IOVA Health Care
- BKU Finance
- Exchange
- IOVA Nasdaq
- BKU Nasdaq
- Market Cap
- IOVA 1.0B
- BKU N/A
- IPO Year
- IOVA N/A
- BKU 2011
- Fundamental
- Price
- IOVA $1.75
- BKU $33.85
- Analyst Decision
- IOVA Strong Buy
- BKU Hold
- Analyst Count
- IOVA 9
- BKU 11
- Target Price
- IOVA $15.50
- BKU $40.45
- AVG Volume (30 Days)
- IOVA 13.9M
- BKU 931.7K
- Earning Date
- IOVA 05-08-2025
- BKU 04-28-2025
- Dividend Yield
- IOVA N/A
- BKU 3.61%
- EPS Growth
- IOVA N/A
- BKU 38.76
- EPS
- IOVA N/A
- BKU 3.21
- Revenue
- IOVA $212,679,000.00
- BKU $972,198,000.00
- Revenue This Year
- IOVA $182.20
- BKU $15.93
- Revenue Next Year
- IOVA $62.10
- BKU $6.75
- P/E Ratio
- IOVA N/A
- BKU $10.70
- Revenue Growth
- IOVA 11070.12
- BKU 11.13
- 52 Week Low
- IOVA $2.70
- BKU $26.78
- 52 Week High
- IOVA $13.60
- BKU $44.45
- Technical
- Relative Strength Index (RSI)
- IOVA 23.78
- BKU 54.65
- Support Level
- IOVA $3.02
- BKU $32.97
- Resistance Level
- IOVA $3.31
- BKU $34.80
- Average True Range (ATR)
- IOVA 0.24
- BKU 1.07
- MACD
- IOVA -0.09
- BKU 0.27
- Stochastic Oscillator
- IOVA 4.81
- BKU 75.70
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.